• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Knauss Robert Brown was granted 19,132 shares, increasing direct ownership by 53% to 54,933 units (SEC Form 4)

    5/27/25 4:48:11 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Knauss Robert Brown

    (Last) (First) (Middle)
    C/O WARBURG PINCUS & CO.
    450 LEXINGTON AVENUE

    (Street)
    NEW YORK NY 10017

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sotera Health Co [ SHC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/22/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.01 par value per share ("Common Stock") 05/22/2025 A 19,132(1) A $0 54,933(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These securities consist of 19,132 restricted stock units ("RSUs") that were granted on May 22, 2025, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date.
    2. These securities consist of 19,132 RSUs and 35,801 shares of Common Stock.
    Remarks:
    The Power of Attorney for Mr. Knauss is filed as an exhibit to the Form 3 filed with the Securities and Exchange Commission on October 24, 2022, which is hereby incorporated by reference.
    Matthew J. Klaben, Attorney-in-Fact 05/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    SEC Filings

    See more
    • SEC Form SD filed by Sotera Health Company

      SD - Sotera Health Co (0001822479) (Filer)

      6/2/25 4:44:07 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sotera Health Co (0001822479) (Filer)

      5/23/25 4:07:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Goldman initiated coverage on Sotera Health with a new price target

      Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

      12/6/24 8:14:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Piper Sandler initiated coverage on Sotera Health with a new price target

      Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

      5/21/24 7:45:20 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

      SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

      3/4/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Flynn Karen was granted 19,132 shares, increasing direct ownership by 95% to 39,221 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      5/27/25 4:49:27 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Director Knauss Robert Brown was granted 19,132 shares, increasing direct ownership by 53% to 54,933 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      5/27/25 4:48:11 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Director Wheadon David E. was granted 19,132 shares, increasing direct ownership by 34% to 74,912 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      5/27/25 4:46:51 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care